公开(公告)号：US12029711B1

公开(公告)日：2024-07-09

申请号：US18608735

申请日：2024-03-18

申请人： SpringWorks Therapeutics, Inc.

发明人： Piero L. Ruggiero ,  Kristin Patterson ,  Mark Hatcher ,  Jiping Liu ,  Uchenna H. Iloeje ,  Abraham J. Langseth

IPC分类号： A61K31/166 ,  A61K9/00 ,  A61K9/48

CPC分类号： A61K31/166 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866

摘要： The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.